The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Commentary|Articles|June 16, 2026
Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026
Author(s)Caroline Seymour, Ashling Wahner
Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
During the
Related to this article
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Advertisement
Advertisement